文献速递白血病

免疫缺陷MISTRG小鼠支持儿童急性髓系白血病异种移植模型中白血病起始细胞的扩增

Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2025-02-21

儿童急性髓系白血病(AML)因耐药白血病起始细胞(LIC)持续存在而易复发,患者来源异种移植(PDX)模型有助于测试新疗法。本研究表明MISTRG与NRGS两种人源化小鼠品系均适合建立AML PDX模型,但MISTRG来源的PDX中LIC频率比NRGS来源的PDX高10倍,这对临床前AML治疗测试和复发模型构建有重要意义。

要点

  • MISTRG与NRGS两种人源化小鼠品系均适合建立儿童AML的PDX模型。
  • MISTRG来源的PDX中LIC频率比NRGS来源的PDX高10倍。
  • LIC频率差异对临床前AML治疗测试和复发模型构建有重要影响。

核心结论

  • MISTRG和NRGS两种人源化小鼠品系均适合建立儿童AML的PDX模型。
  • MISTRG来源的PDX中LIC频率比NRGS来源的PDX高10倍,这对临床前AML治疗测试和复发模型构建有重要意义。

研究设计与样本

  • 本研究比较了MISTRG和NRGS两种人源化小鼠品系用于建立儿童急性髓系白血病(AML)患者来源异种移植(PDX)模型。

主要发现

  • MISTRG来源的PDX中白血病起始细胞(LIC)频率比NRGS来源的PDX高10倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) remains a deadly disease, largely due to the persistence of drug-resistant leukaemia-initiating cells (LICs) which promote relapse. Therefore, effective therapies must target LICs. Patient-derived xenografts (PDXs) are valuable for testing new therapies, though establishing AML PDX models is challenging. Two humanized mouse strains, MISTRG and NRGS, have been developed for this purpose. In this study, we show both are suitable strains for the development of AML PDXs; however, MISTRG-derived PDXs contain 10 times higher LIC frequencies than NRGS-derived PDXs. These differences have crucial implications for preclinical AML therapy testing and modelling relapse models of the disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Connerty P, Xie J, El-Najjar F, et al. Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia. Br J Haematol. 2025. PMID: 39984432. doi:10.1111/bjh.20029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。